The short version of incretin fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-08-03 and is reviewed periodically as new material appears.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Not a small molecule |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist activity |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in water | Also in aqueous buffers |
| Storage | −20 °C or below | Protect from light and moisture |
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
Rare polymorphisms related to this disease include (MTRR):c.1459G>A, (MTRR):c.1623-1624insTA and (MTRR):c.903+469T>C. These mutations, excluding (MTRR):c.1459G>A result in a frame shift, producing premature termination codons. As consequent products are distant from normal, mutant mRNA arises and nonsense mediated decay (FMN) is initiated. The large insertion of 903_904ins140 corresponding to 903+469T>C is most prevalent in CblE pathology. The activation of an enhanced splicer within intron 6 is incomplete, producing small quantities of normal spliced MTRR mRNA. Prenatal diagnosis of this condition is possible using [14C] methyltetrahydrofolate. Mutation analysis in native chorionic villi and [14C] formate in amino acids within these villi or cultured amniocytes is indicative of the CblE defect. Additionally, macrocytic anemia is a typical feature of the CblE defect and can be corrected though OH-Cobalamin administration or folate supplementation.
E. coli is one of the most widely used expression hosts, and DNA is normally introduced in a plasmid expression vector. The techniques for overexpression in E. coli are well developed and work by increasing the number of copies of the gene or increasing the binding strength of the promoter region so assisting transcription. For example, a DNA sequence for a protein of interest could be cloned or subcloned into a high copy-number plasmid containing the lac (often LacUV5) promoter, which is then transformed into the bacterium E. coli. Addition of IPTG (a lactose analog) activates the lac promoter and causes the bacteria to express the protein of interest. E. coli strain BL21 and BL21(DE3) are two strains commonly used for protein production. As members of the B lineage, they lack lon and OmpT proteases, protecting the produced proteins from degradation. The DE3 prophage found in BL21(DE3) provides T7 RNA polymerase (driven by the LacUV5 promoter), allowing for vectors with the T7 promoter to be used instead.
50% androgens 30% mixed 10% steroids 10% hormone-inactive The average time from the onset of symptoms to diagnosis is six months. Approximately 70% of tumors can be completely removed surgically. The current state of research is considered insufficient. The few available comparisons between adrenocortical carcinomas in adults and children indicate significant differences. Therefore, findings obtained so far in adults cannot be readily applied to children. To close these knowledge gaps and to be able to determine suitable therapies for children, a better molecular biological understanding of the prognosis and tumor biology of adrenocortical tumors in children is needed. Currently, the main research questions are:
The Royal Marine battalion and Royal Marine Artillery were to go to Quebec under the command of Beckwith, leaving Napier a brigade of 1,000 infantry and three artillery pieces. It had been proposed to move the 102d to operations in the American south, but this was not carried out. Napier transferred by exchange to the 50th Regiment of Foot in September 1813. Detachments of the 102d Regiment of Foot remained on both sides of the border between the British colony of New Brunswick and the U.S. state of Maine after the war's end in December 1814 at Moose Island, modern day Eastport, Maine, United States. The Treaty of Ghent was signed on 24 December 1814 by the negotiators, ratified by the Prince Regent on 27 December, and by the United States President on 17 February, ending the war. After three years at New Brunswick, it embarked in the autumn of 1817 to return to England under the command of Major Gustavus Rochford. After the end of the wars against Napoleonic France and the United States, the British Army disbanded many units for the sake of economy. The regiment was reorganized as the 100th Regiment of Foot in 1816. The regiment was the last British unit to occupy the United States; the last detachments returned to Chatham in England, where the regiment was disbanded on 24 March 1818.
The grouping consistent with transfer of nitrogenous groups is EC 2.6. This includes enzymes like transaminase (also known as "aminotransferase"), and a very small number of oximinotransferases and other nitrogen group transferring enzymes. EC 2.6 previously included amidinotransferase but it has since been reclassified as a subcategory of EC 2.1 (single-carbon transferring enzymes). In the case of aspartate transaminase, which can act on tyrosine, phenylalanine, and tryptophan, it reversibly transfers an amino group from one molecule to the other. The reaction, for example, follows the following order: L-aspartate +2-oxoglutarate
Sources: en.wikipedia.org
== # == 2-amino-4-deoxychorismate dehydrogenase - 2-dehydropantolactone reductase (B-specific) - 2-methylacyl-CoA dehydrogenase - 2-nitropropane dioxygenase - 2-oxobutyrate synthase - (2,3-dihydroxybenzoyl)adenylate synthase - 2,4-Dihydroxy-1,4-benzoxazin-3-one-glucoside dioxygenase - 2010107G12Rik - 27-hydroxycholesterol 7alpha-monooxygenase - 3' end - 3' flanking region - 3-hydroxy-2-methylpyridinecarboxylate dioxygenase - 3-Ketosteroid 9alpha-monooxygenase - 3-oxoacyl-(acyl-carrier-protein) reductase (NADH) - (3,5-dihydroxyphenyl)acetyl-CoA 1,2-dioxygenase - 3(or 17)a-hydroxysteroid dehydrogenase - 3110001I22Rik - 3alpha-hydroxyglycyrrhetinate dehydrogenase - 4932414N04Rik - 3alpha-hydroxysteroid dehydrogenase (A-specific) - 3alpha,7alpha,12alpha-trihydroxy-5beta-cholestanoyl-CoA 24-hydroxylase - 3alpha,7alpha,12alpha-trihydroxycholestan-26-al 26-oxidoreductase - 4-Cresol dehydrogenase (hydroxylating) - 4-Hydroxycyclohexanecarboxylate dehydrogenase - 4-hydroxyphenylacetaldehyde oxime monooxygenase - 4-hydroxyphenylpyruvate oxidase - 4-Nitrophenol 4-monooxygenase - 4933425L06Rik - 5' end - 5' flanking region - 5-pyridoxate dioxygenase - 6-endo-hydroxycineole dehydrogenase - 7-deoxyloganin 7-hydroxylase - 7beta-hydroxysteroid dehydrogenase (NADP+) - 8-oxocoformycin reductase - 12beta-hydroxysteroid dehydrogenase - 25-hydroxycholesterol 7α-hydroxylase -
== External links == "Form and Function: The First Sequence of an Enzyme, Ribonuclease". The Rockefeller University. William Howard Stein on Nobelprize.org with the Nobel Lecture, December 11, 1972 The Chemical Structures of Pancreatic Ribonuclease and Deoxyribonuclease
=== In the cosmetic industry === Lighter skin complexion has been associated with youth and beauty across various Asian cultures. Recent research by cosmetic companies has been focused on the development of novel whitening agents that selectively suppress tyrosinase activity to reduce hyperpigmentation while avoiding cytotoxicity of healthy melanocytes. Traditional pharmacological agents such as corticosteroids, hydroquinone, and amino numeric chloride lighten skin through the inhibition of melanocyte maturation. However, these agents are associated with adverse effects. Cosmetic companies have been focused on developing novel whitening agents that selectively suppress the activity of tyrosinase to reduce hyperpigmentation while avoiding melanocyte cytotoxicity as tyrosinase is the rate-limiting step of the melanogenesis pathway.
The event that precipitated the Cold War in continental Asia was the resumption of the Chinese Civil War (1927–1949) fought between the anti-communist Kuomintang and the Chinese Communist Party. After military defeat exiled Generalissimo Chiang Kai-shek and his Kuomintang nationalist government to Formosa island (Taiwan), Mao Zedong established the People's Republic of China on 1 October 1949.
Sources: en.wikipedia.org
=== Epigenetic clock analysis of human HGPS === Fibroblast samples from children with progeria syndrome exhibit accelerated epigenetic aging effects according to the epigenetic clock for skin and blood samples.
After the internationalization of the war, several among them stepped off the fence and entered the political contest. The French strategy of inducing the Viet Minh to attack well-defended bases in remote areas at the end of their logistical trails succeeded at the Battle of Nà Sản. French efforts were hampered by the limited usefulness of tanks in forest terrain, the lack of a strong air force, and reliance on soldiers from French colonies. The Viet Minh used novel and efficient tactics, including direct artillery fire, convoy ambushes, and anti-aircraft weaponry to impede land and air resupplies, while recruiting a sizable regular army facilitated by large popular support. They used guerrilla warfare doctrine and instruction from China, and used war materiel provided by the Soviet Union. This combination proved fatal for the French bases, culminating in a decisive French defeat at the Battle of Dien Bien Phu. An estimated 400,000 to 842,707 soldiers died during the war as well as between 125,000 and 400,000 civilians. Both sides committed war crimes, including killings of civilians (such as the Mỹ Trạch massacre by French troops), rape and torture. The State of Vietnam gained full independence legally in June 1954, although the transfer of power was not yet complete. Despite gaining a great military advantage and controlling most of the country's territory, the Viet Minh had to accept a separation at the 17th parallel due to diplomatic pressure from the Chinese.
=== High throughput crystallization screening === High through-put methods exist to help streamline the large number of experiments required to explore the various conditions that are necessary for successful crystal growth. There are numerous commercial kits available for order which apply preassembled ingredients in systems guaranteed to produce successful crystallization. Using such a kit, a scientist avoids the hassle of purifying a protein and determining the appropriate crystallization conditions. Liquid-handling robots can be used to set up and automate large number of crystallization experiments simultaneously. What would otherwise be slow and potentially error-prone process carried out by a human can be accomplished efficiently and accurately with an automated system. Robotic crystallization systems use the same components described above, but carry out each step of the procedure quickly and with a large number of replicates. Each experiment utilizes tiny amounts of solution, and the advantage of the smaller size is two-fold: the smaller sample sizes not only cut-down on expenditure of purified protein, but smaller amounts of solution lead to quicker crystallizations. Each experiment is monitored by a camera which detects crystal growth.
Sources: en.wikipedia.org
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.
Earlier incretin therapies engage one or two receptors. Retatrutide adds glucagon receptor activity, which may raise energy expenditure. Whether this produces larger clinical benefits is still being tested.
It has completed phase 2 trials and moved into later-stage evaluation. No regulator has granted approval. Access outside research settings is not authorized.
As of the mid-2020s retatrutide remains investigational and is not an approved medicine in the United States or the European Union. It has been supplied mainly to participants in clinical trials. Labels and availability can change, so regulatory listings should be checked directly.